MedTrace Logo

Non-interventional Observational Study on WHO-5 Questionnaire Application in Parkinson's Disease

NCT00752388 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1588

Last updated 2013-11-19

No results posted yet for this study

Summary

To assess the predictive value of sequential administration of WHO-5 and MDI (Major Depression Inventory) for the clinical management of Parkinson Disease (PD) patients by

* determination of the prevalence of depression in PD patients, based on MDI severity categories and the self-rating scale WHO-5, where poor well being was indicated.
* exploration of influencing factors (PD status, therapeutic status) on the prevalence of MDI depression categories.

Conditions

  • Parkinson Disease

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2008-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00752388 on ClinicalTrials.gov